Your session is about to expire
← Back to Search
Endoplasmic Reticulum Stress Relieving Agent
Taurourodeoxycholic Acid (TUDCA) for Type 1 Diabetes
Phase 2
Waitlist Available
Led By Rudolph Leibel, MD
Research Sponsored by Robin Goland, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
All Individual Drugs Already Approved
Summary
This trial tests TUDCA, a medication that reduces cell stress, on patients with type 1 diabetes. The aim is to help insulin-producing cells survive and function better, potentially slowing down or preventing the disease's progression.
Eligible Conditions
- Type 1 Diabetes
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
C-peptide measurement as reflection of insulin secretion
Secondary study objectives
Endoplasmic reticulum stress
liver function tests
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Taurourodeoxycholic Acid (TUDCA)Experimental Treatment1 Intervention
TUDCA 1750 mg/day x 12 months
Group II: Sugar pill (placebo)Placebo Group1 Intervention
Placebo at same dose, frequency, and duration as experimental treatment
Find a Location
Who is running the clinical trial?
Juvenile Diabetes Research FoundationOTHER
234 Previous Clinical Trials
142,061 Total Patients Enrolled
Robin Goland, MDLead Sponsor
Rudolph Leibel, MDPrincipal InvestigatorColumbia University
Share this study with friends
Copy Link
Messenger